ANAB
AnaptysBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$56.80
−1.15%Next report
Analyst consensus
- Next report date
- Sep 9, 2026
- EPS estimate
- -$0.41
- Revenue estimate
- $6.7M
Latest reported
- Last report date
- May 12, 2026
- EPS actual
- -$1.84
- EPS estimate
- -$0.32
- Revenue actual
- $25.6M
- Revenue estimate
- $18.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -48.3%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $83
- PT range
- $70 – $95
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 10, 2026